Despite no direct effect of LAG-3 blockade on NK cell-mediated cytotoxicity was observed, calcein-AM cytotoxicity assays revealed that combination of LAG-3 blockade and lenalidomide enhances rituximab-mediated ADCC activity of NK cells from patients with CLL (Figure 5D). The gene discussed is LAG3; the disease is B-cell chronic lymphocytic leukemia.